Trade Biomea Fusion, Inc. - BMEA CFD

Add to favourite

11.22

1.66%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.12

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Biomea Fusion Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	11.45
Open*	11.39
1-Year Change*	-54.35%
Day's Range*	10.96 - 11.39
52 wk Range	8.04-43.69
Average Volume (10 days)	830.27K
Average Volume (3 months)	26.04M
Market Cap	506.31M
P/E Ratio	-100.00K
Shares Outstanding	35.71M
Revenue	N/A
EPS	-3.34
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 17, 2024	11.45	-0.46	-3.86%	11.91	12.01	11.39
Apr 16, 2024	11.90	-0.36	-2.94%	12.26	12.53	11.76
Apr 15, 2024	12.48	-0.28	-2.19%	12.76	13.26	12.10
Apr 12, 2024	12.94	-0.12	-0.92%	13.06	13.61	12.56
Apr 11, 2024	13.25	0.57	4.50%	12.68	13.38	12.53
Apr 10, 2024	12.70	0.44	3.59%	12.26	12.81	12.21
Apr 9, 2024	12.75	0.28	2.25%	12.47	12.80	12.15
Apr 8, 2024	12.46	-0.25	-1.97%	12.71	12.90	12.38
Apr 5, 2024	12.67	0.11	0.88%	12.56	13.20	11.98
Apr 4, 2024	12.55	-1.41	-10.10%	13.96	14.33	12.49
Apr 3, 2024	13.90	0.94	7.25%	12.96	13.91	12.90
Apr 2, 2024	12.73	-1.06	-7.69%	13.79	13.92	12.52
Apr 1, 2024	15.27	0.11	0.73%	15.16	16.16	14.38
Mar 28, 2024	14.88	-0.35	-2.30%	15.23	15.66	14.80
Mar 27, 2024	15.29	0.23	1.53%	15.06	15.51	14.61
Mar 26, 2024	14.90	-0.56	-3.62%	15.46	15.89	14.90
Mar 25, 2024	15.28	-0.43	-2.74%	15.71	16.11	15.21
Mar 22, 2024	15.83	-0.89	-5.32%	16.72	16.83	15.79
Mar 21, 2024	16.92	0.96	6.02%	15.96	17.15	15.86
Mar 20, 2024	15.74	0.57	3.76%	15.17	15.74	14.73

Biomea Fusion, Inc. Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2022	2021	2020	2019
Total revenue	0	0	0	0
Total Operating Expense	83.634	41.667	5.327	1.195
Selling/General/Admin. Expenses, Total	20.921	13.671	1.656	0.103
Research & Development	62.713	27.996	3.671	1.092
Operating Income	-83.634	-41.667	-5.327	-1.195
Interest Income (Expense), Net Non-Operating	1.806	0.1	0.003	-0.003
Net Income Before Taxes	-81.828	-41.567	-5.324	-1.198
Net Income After Taxes	-81.828	-41.567	-5.324	-1.198
Net Income Before Extra. Items	-81.828	-41.567	-5.324	-1.198
Net Income	-81.828	-41.567	-5.324	-1.198
Income Available to Common Excl. Extra. Items	-81.828	-41.567	-5.324	-1.198
Income Available to Common Incl. Extra. Items	-81.828	-41.567	-5.324	-1.198
Diluted Net Income	-81.828	-41.567	-5.324	-1.198
Diluted Weighted Average Shares	29.2718	23.8585	28.7679	28.7679
Diluted EPS Excluding Extraordinary Items	-2.79546	-1.74223	-0.18507	-0.04164
Dividends per Share - Common Stock Primary Issue			0	0
Diluted Normalized EPS	-2.79546	-1.74223	-0.18507	-0.04164

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	27.657	30.031	26.276	23.484	17.474
Selling/General/Admin. Expenses, Total	5.719	5.636	5.737	5.242	4.892
Research & Development	21.938	24.395	20.539	18.242	12.582
Operating Income	-27.657	-30.031	-26.276	-23.484	-17.474
Interest Income (Expense), Net Non-Operating	2.766	0.98	0.962	0.594	0.216
Net Income Before Taxes	-24.891	-29.051	-25.314	-22.89	-17.258
Net Income After Taxes	-24.891	-29.051	-25.314	-22.89	-17.258
Net Income Before Extra. Items	-24.891	-29.051	-25.314	-22.89	-17.258
Net Income	-24.891	-29.051	-25.314	-22.89	-17.258
Income Available to Common Excl. Extra. Items	-24.891	-29.051	-25.314	-22.89	-17.258
Income Available to Common Incl. Extra. Items	-24.891	-29.051	-25.314	-22.89	-17.258
Diluted Net Income	-24.891	-29.051	-25.314	-22.89	-17.258
Diluted Weighted Average Shares	35.3483	29.5865	29.4435	29.319	29.1964
Diluted EPS Excluding Extraordinary Items	-0.70416	-0.9819	-0.85975	-0.78072	-0.5911
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.70416	-0.9819	-0.85975	-0.78072	-0.5911

Annual
Quarterly

	2022	2021	2020	2019
Total Current Assets	117.819	176.561	62.223	0.265
Cash and Short Term Investments	113.049	173.516	61.695	0.239
Cash & Equivalents	111.899	145.736	61.695	0.239
Prepaid Expenses	4.77	3.045	0.492	0.015
Other Current Assets, Total			0.036	0.011
Total Assets	129.307	185.705	62.526	0.265
Property/Plant/Equipment, Total - Net	7.992	5.687	0.291	0
Property/Plant/Equipment, Total - Gross	8.908	5.944	0.299	0
Accumulated Depreciation, Total	-0.916	-0.257	-0.008	0
Other Long Term Assets, Total	3.496	1.581	0.012	0
Total Current Liabilities	19.101	4.637	1.619	0.286
Accounts Payable	6.826	1.329	0.727	0.271
Accrued Expenses	11.639	2.828	0.856	0.015
Notes Payable/Short Term Debt	0	0	0.036	0
Total Liabilities	20.768	6.922	1.619	0.286
Total Long Term Debt	0	0	0	0
Total Equity	108.539	178.783	60.907	-0.021
Preferred Stock - Non Redeemable, Net		0	55.738	0
Common Stock	0.003	0.003	0.001	0.001
Additional Paid-In Capital	240.107	228.532	13.343	2.829
Retained Earnings (Accumulated Deficit)	-131.57	-49.742	-8.175	-2.851
Total Liabilities & Shareholders’ Equity	129.307	185.705	62.526	0.265
Total Common Shares Outstanding	29.5616	29.1156	28.7679	28.7679
Short Term Investments	1.15	27.78
Long Term Investments	0	1.876
Other Current Liabilities, Total	0.636	0.48
Other Liabilities, Total	1.667	2.285
Other Equity, Total	-0.001	-0.01

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	202.504	225.936	88.931	117.819	138.861
Cash and Short Term Investments	199.09	222.908	86.3	113.049	133.458
Cash & Equivalents	199.09	222.908	86.3	111.899	132.311
Short Term Investments	0	0	0	1.15	1.147
Total Receivables, Net
Accounts Receivable - Trade, Net
Prepaid Expenses	3.414	3.028	2.631	4.77	5.403
Other Current Assets, Total
Total Assets	225.087	248.674	112.638	129.307	145.05
Property/Plant/Equipment, Total - Net	17.385	18.481	19.467	7.992	5.345
Property/Plant/Equipment, Total - Gross	19.396	20.073	20.676	8.908	6.078
Accumulated Depreciation, Total	-2.011	-1.592	-1.209	-0.916	-0.733
Long Term Investments				0	0.01
Other Long Term Assets, Total	5.198	4.257	4.24	3.496	0.834
Total Current Liabilities	16.21	14.357	18.774	19.101	12.589
Accounts Payable	3.194	4.154	5.329	6.826	1.592
Accrued Expenses	12.852	9.804	13.02	11.639	10.569
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.164	0.399	0.425	0.636	0.428
Total Liabilities	25.475	24.369	29.509	20.768	14.415
Total Long Term Debt	0	0	0	0	0
Total Equity	199.612	224.305	83.129	108.539	130.635
Preferred Stock - Non Redeemable, Net					0
Common Stock	0.004	0.004	0.003	0.003	0.003
Additional Paid-In Capital	413.549	409.813	243.747	240.107	236.901
Retained Earnings (Accumulated Deficit)	-213.941	-185.512	-160.621	-131.57	-106.256
Other Equity, Total	0	0	0	-0.001	-0.013
Total Liabilities & Shareholders’ Equity	225.087	248.674	112.638	129.307	145.05
Total Common Shares Outstanding	35.6988	35.6303	29.6511	29.5616	29.3888
Other Liabilities, Total	9.265	10.012	10.735	1.667	1.826

Annual
Quarterly

	2022	2021	2020	2019
Net income/Starting Line	-81.828	-41.567	-5.324	-1.198
Cash From Operating Activities	-62.417	-35.438	-4.459	-1.279
Cash From Operating Activities	0.691	0.249	0.008	0
Non-Cash Items	11.051	7.454	0.446	0
Changes in Working Capital	7.669	-1.574	0.411	-0.081
Cash From Investing Activities	27.341	-33.355	-0.051	0
Capital Expenditures	-1.03	-3.171	-0.051	0
Cash From Financing Activities	1.239	153.185	65.966	1.44
Issuance (Retirement) of Stock, Net	1.239	153.221	65.93	1.44
Issuance (Retirement) of Debt, Net	0	-0.036	0.036	0
Net Change in Cash	-33.837	84.392	61.456	0.161
Other Investing Cash Flow Items, Total	28.371	-30.184

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-29.051	-81.828	-56.514	-33.624	-16.366
Cash From Operating Activities	-24.044	-62.417	-42.216	-25.421	-9.994
Cash From Operating Activities	0.293	0.691	0.51	0.336	0.166
Non-Cash Items	3.846	11.051	8.182	5.297	2.57
Changes in Working Capital	0.868	7.669	5.606	2.57	3.636
Cash From Investing Activities	-1.756	27.341	28.042	27.817	20.442
Capital Expenditures	-2.906	-1.03	-0.318	-0.368	-0.095
Other Investing Cash Flow Items, Total	1.15	28.371	28.36	28.185	20.537
Cash From Financing Activities	0.201	1.239	0.749	0.349	0.031
Issuance (Retirement) of Stock, Net	0.201	1.239	0.749	0.349	0.031
Issuance (Retirement) of Debt, Net		0	0	0	0
Net Change in Cash	-25.599	-33.837	-13.425	2.745	10.479

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biomea Fusion, Inc. Company profile

About Biomea Fusion Inc

Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biomea Fusion Inc revenues was not reported. Net loss increased from $5.3M to $41.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$1.74.

Industry:

Biotechnology & Medical Research (NEC)

900 Middlefield Road, 4th Floor
REDWOOD CITY
CALIFORNIA 94063
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024